您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Betaxolol
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Betaxolol
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Betaxolol图片
CAS NO:63659-18-7
包装与价格:
包装价格(元)
10mg电议
50mg电议

产品介绍
倍他洛尔是一种选择性β1肾上腺素受体阻滞剂,可用于高血压和青光眼的研究。
Cas No.63659-18-7
别名倍他洛尔
化学名1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-(isopropylamino)propan-2-ol
Canonical SMILESCC(NCC(O)COC1=CC=C(CCOCC2CC2)C=C1)C
分子式C18H29NO3
分子量307.43
溶解度≥ 30.7mg/mL in DMSO
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Betaxolol is a selective beta1 adrenergic receptor blocker used in the treatment of hypertension and glaucoma.Target: Beta1 Adrenergic ReceptorBetaxolol is a cardioselective beta-adrenergic receptor blocking agent. Betaxolol (5 mg/kg via i.p. injection) was administered at 24 and then 44 h following the final chronic cocaine administration. Animals treated with betaxolol during cocaine withdrawal exhibited a significant attenuation of anxiety-like behavior characterized by increased time spent in the open arms and increased entries into the open arms compared to animals treated with only saline during cocaine withdrawal. Betaxolol did not produce anxiolytic-like effects in control animals treated chronically with saline [1]. Betaxolol produces less systemic beta 2- and possibly beta 1-adrenergic receptor blockade than either timolol or levobunolol. Betaxolol may be relatively safer to use in patients with reactive airway disease than either timolol or levobunolol [2].

References:
[1]. Rudoy, C.A. and E.J. Van Bockstaele, Betaxolol, a selective beta(1)-adrenergic receptor antagonist, diminishes anxiety-like behavior during early withdrawal from chronic cocaine administration in rats. Prog Neuropsychopharmacol Biol Psychiatry, 2007. 31(5): p. 1119-29.
[2]. Lesar, T.S., Comparison of ophthalmic beta-blocking agents. Clin Pharm, 1987. 6(6): p. 451-63.